Topic:

M&A

Latest Headlines

Latest Headlines

Bayer sees IPO cash as war chest for new consumer deals

Once Bayer raises the billions it anticipates from an IPO of its plastics business, it plans to pay off debt. But after that? Expect some OTC acquisitions, the company's CEO says.

UPDATED: Stryker said to be interested in buying Smith & Nephew (once again)

The clock is about to strike 6 months since Stryker expressed interest in acquiring Smith & Nephew, only to be dissuaded by a rise in that company's stock price once news of the potential deal broke out. And so begins the speculation that Stryker will actually make a bid on the fellow orthopedics company this time around.

CRO Ricerca stays alive after buyer swoops in

Ohio-headquartered CRO Ricerca Biosciences can put off its liquidation plans, as the company has found an acquirer to keep its doors open just ahead of a self-imposed deadline.

Petco boosts animal health presence with purchase of Drs. Foster & Smith

Pet retail giant Petco of San Diego announced Wednesday that it is acquiring online and catalog company Drs. Foster & Smith, which is owned by veterinarians and based in Wisconsin.

Zimmer once again gives European regulators more time to rule on Biomet deal

The European Commission was scheduled to rule on Zimmer's planned acquisition of fellow orthopedics company Biomet by March 11. Now the deadline has been extended by a "limited number of days," Zimmer says.

Medtronic looks beyond Type 1 with a diabetes reorg

Medtronic's fastest growing business is in diabetes, which gained 10% to $430 million in the most recent quarter over a year ago. Now the medical device giant is looking to expand beyond its dominance in Type 1 diabetes that is based on the success of its insulin pump MiniMed. During an earnings call, Medtronic disclosed that it reorganized its diabetes group last quarter.

UPDATED: Has Allergan failure weakened Valeant CEO's M&A hand?

Valeant CEO J. Michael Pearson upheld his reputation as a disciplined bidder when he refused to top Actavis' $66 billion bid for Allergan. But now that his company has nothing to show for the past 7 months, has its dealmaking reputation taken a hit?

Actavis' merger cost-cutting isn't Valeant-style. But it's still $1.8B

With the excitement over Actavis' white-knight swoop-in for Allergan out of the way, it's time to take a closer look at the transaction--and how it compares with Valeant's proposed Allergan tie-up.

Japan's largest CMO, Bushu, gets new private equity owner

In a deal valued at more than $660 million, Baring Private Equity Asia showed up Monday as the buyer of a Japanese CMO and Tokio Marine Capital as the seller.

Actavis officially steals Allergan from Valeant with $66B buyout

With Actavis and Allergan's deal agreement, the Botox maker is getting what it's wanted for months--a way to thwart hostile bidder Valeant. And Actavis? It's getting a glimpse of a future that holds $23 billion in annual revenue, and that would officially punch its ticket into Big Pharma.